Duffuler Pauline, Bhullar Khushwant S, de Campos Zani Stepheny C, Wu Jianping
Department of Agricultural Food & Nutritional Science, University of Alberta, Edmonton, Alberta T6G 2P5, Canada.
Department of Pharmacology, University of Alberta, Edmonton, Alberta T6G 2P5, Canada.
J Agric Food Chem. 2022 Mar 30;70(12):3585-3595. doi: 10.1021/acs.jafc.1c06289. Epub 2022 Mar 18.
Chronic diseases, including metabolic diseases, have become a worldwide public health issue. Research regarding the use of bioactive peptides or protein hydrolysates derived from food, as the diet-based strategies for the prevention and mitigation of chronic diseases, has increased exponentially in the past decades. Numerous and studies report the efficacy and safety of food-derived bioactive peptides and protein hydrolysates as antihypertensive, anti-inflammatory, antidiabetic, and antioxidant agents. However, despite promising preclinical results, an inadequate understanding of their mechanisms of action and pharmacokinetics restrict their clinical translation. Commercialization of bioactive peptides can be further hindered due to scarce information regarding their efficacy, safety, bitter taste, as well as the lack of a cost-effective method of production. This review provides an overview of the current clinical evidence and challenges to commercial applications of food-derived bioactive peptides and protein hydrolysates for the prevention and alleviation of chronic diseases.
包括代谢性疾病在内的慢性病已成为一个全球性的公共卫生问题。在过去几十年中,关于使用源自食物的生物活性肽或蛋白质水解物作为基于饮食的慢性病预防和缓解策略的研究呈指数级增长。大量研究报告了源自食物的生物活性肽和蛋白质水解物作为抗高血压、抗炎、抗糖尿病和抗氧化剂的功效和安全性。然而,尽管临床前结果很有前景,但对其作用机制和药代动力学的了解不足限制了它们的临床转化。由于关于其功效、安全性、苦味的信息稀缺,以及缺乏具有成本效益的生产方法,生物活性肽的商业化可能会受到进一步阻碍。本综述概述了目前关于源自食物的生物活性肽和蛋白质水解物预防和缓解慢性病的临床证据以及商业应用面临的挑战。